相关实验视频

Updated: Jun 15, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

通过细胞外囊泡传递IL-12小型循环,用于膀癌的免疫疗法

Zhiyuan Wu^1,2, Wei Li^1,2,3,4, Melissa Tan^1,2,5

¹Department of Pharmacology and Institute for Digital Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

Cell proliferation

|August 28, 2024

概括

红细胞衍生的细胞外囊泡 (RBCEVs) 能够有效地将Interleukin-12 (IL-12) 基因传递给膀癌细胞. 这种新的方法抑制了瘤的生长,并刺激了抗癌免疫反应,提供了更安全的治疗策略.

科学领域:

生物技术是生物技术.
癌症治疗癌症治疗
基因传递基因传递

背景情况:

介质蛋白-12 (IL-12) 在癌症治疗中表现有前途,但由于剂量限制性毒性而面临挑战.
直接输送瘤基因提供了一种提高IL-12疗效和减少系统性副作用的策略.

研究的目的:

为了评估红细胞衍生的细胞外囊泡 (RBCEVs) 作为交付平台的介质素-12 (IL-12) 质粒DNA.
在膀癌模型中评估RBCEV介导IL-12基因传递的疗效.

主要方法:

在RBCEV中装有编码IL-12的微圆等离子体.
在MB49膀癌细胞和小鼠脊髓细胞中分析了IL-12表达和免疫反应.
在小鼠膀癌模型中进行了IL-12等离子体装载RBCEV的内输送.

主要成果:

RBCEVs有效地加载并将IL-12微循环等离子体传递给癌细胞,导致与父母等离子体相比,转基因表达更高.
通过RBCEV介导的IL-12表达在小鼠脊髓细胞中诱导了显著的免疫反应.
用IL-12等离子体装载的RBCEV进行瘤内注射,抑制了瘤生长,增强了抗瘤免疫力,并促进了免疫细胞透.

结论:

RBCEVs代表了一种有希望的,安全的,可重剂量的核酸药物输送平台,用于IL-12.
这种方法有可能通过使向的IL-12输送成为可能,从而改善癌症免疫疗法.

更多相关视频

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.